Abstract:As a novel co-receptor for vascular endothelial growth factor (VEGF), neuropilin receptor type-1 (NRP-1) is overexpressed in several cancers and metastases, and serves as an attractive target for cancer molecular imaging and therapy. Previous single photon emission computerized tomography (SPECT) studies demonstrated that the small NRP-1-targeting peptides 99mTc-MA-ATWLPPR and 99mTc-CK3 showed poor tumor imaging quality, because of their rapid blood clearance and very low tumor uptake. Compared with small peptides, monoclonal antibodies (mAbs) can improve imaging of NRP-1-expression, due to their high affinity, specificity and slow extraction. A6-11-26 is a novel monoclonal antibody against NRP-1 b1b2 domain that exhibits inhibition of tumor growth in NPR-1-expressing preclinical models. The aim of the present study was to develop the 131I-labeled anti-NRP-1 monoclonal antibody A6-11-26 as a SPECT probe for imaging of NRP-1-positive tumor. An anti-NRP-1 monoclonal antibody (A6-11-26) was produced by hybridomas and was labeled with iodine-131 by the iodogen method. In vitro, the radiolabeling efficiency, radiochemical purity, immunoreactive fraction and stability were assessed. Binding affinity and specificity of 131I‑A6-11-26 to NRP-1 were evaluated using human glioblastoma U87MG cells. In vivo, biodistribution and SPECT/CT studies were conducted on mice bearing U87MG xenografts after the injection of 131I-A6-11-26 with or without co-injection of unlabeled A6-11-26 antibody. A6-11-26 was generated successfully by hybridoma with high purity (>95%) and was labeled with iodine-131 within 60 min with high labelling efficiency (95.46±3.34%), radiochemical purity (98.23±1.41%). 131I-A6-11-26 retained its immunoreactivity and also displayed excellent stability in mouse serum and PBS solution during 1 to 96 h. Cell uptake assays showed high NRP-1-specific uptake (15.80±1.30% applied activity at 6 h) in U87MG cells. 131I-A6-11-26 bound to NRP-1 with low nanomolar affinity (KD=1.67±0.14 nM) in U87MG cells. In vivo, biodistribution study demonstrated targeting of U87MG glioma xenografts was NRP-1 specific. The tumor uptake was 6.00±1.24%ID/g at 24 h, and the tumor to muscle ratio was 3.20±0.30 at 24 h, and reached the highest level of 6.13±0.24 at 120 h after injection. SPECT imaging studies revealed that 131I-A6-11-26 could clearly identify U87MG tumors with good contrast, especially at 72-120 h after injection. The present study demonstrates that 131I-A6-11-26 is capable of detecting lesions in an NRP-1-expressing tumor with high target selectivity, and may offer a promising SPECT agent for NRP-1 expression positive tumor and encourage further investigation.

A Ga-68 Labeled Peptide for Imaging of {alpha}v{beta}6 Positive Tumor

188Re-Labeled GX1 Dimer As a Novel Dual-Functional Probe Targeting TGM2 for Imaging and Antiangiogenic Therapy of Gastric Cancer

<SUP>68</SUP>Ga-Labeled GX1 Dimer: A Novel Probe for PET/Cerenkov Imaging Targeting Gastric Cancer

99mTc-labeled cystine knot peptide targeting integrin αvβ6 for tumor SPECT imaging.

Ga-68-Labeled Cyclic Rgd Dimers With Gly(3) And Peg(4) Linkers: Promising Agents For Tumor Integrin Alpha(V)Beta(3) Pet Imaging

Tc-99m-Labeled Cystine Knot Peptide Targeting Integrin Alpha(V)Beta(6) For Tumor Spect Imaging

<sup>68</sup>Ga-labeled cyclic RGD dimers with Gly<sub>3</sub> and PEG<sub>4</sub> linkers: promising agents for tumor integrin α<sub>v</sub>β<sub>3</sub> PET imaging

68 Ga-labeled Cyclic RGD Dimers with Gly 3 and PEG 4 Linkers: Promising Agents for Tumor Integrin Α V Β 3 PET Imaging

SPECT Imaging of Neuropilin Receptor Type-1 Expression with 131I-Labeled Monoclonal Antibody.

[99mTc]-labeling and evaluation of a new linear peptide for imaging of glioblastoma as a αvβ3-positive tumor

Radiolabeled Gamma-Aapeptides: A New Class of Pet Tracers

A novel radiofluorinated agouti-related protein for tumor angiogenesis imaging

Integrin Αvβ6–targeted SPECT Imaging for Pancreatic Cancer Detection

Positron Emission Tomography Imaging of Tumor Angiogenesis with a 66Ga-Labeled Monoclonal Antibody.

Radiolabeling and Evaluation of (64)Cu-Dota-f56 Peptide Targeting Vascular Endothelial Growth Factor Receptor 1 in the Molecular Imaging of Gastric Cancer.

A stapled chromogranin A-derived peptide homes in on tumors that express αvβ6 or αvβ8 integrins

Clinical Translation of a 68Ga-Labeled Integrin Αvβ6–targeting Cyclic Radiotracer for PET Imaging of Pancreatic Cancer

Comparing two TAG-72 binding peptides previously identified by phage display as potential imaging agents.

Identification of a Novel ITGαvβ6-Binding Peptide Using Protein Separation and Phage Display

131)I Labeling and Bioactivity Evaluation of a Novel RGD Dimer Targeted to Integrin Αvβ3 Receptor

A New Cyclic RGD Peptide Dimer for Integrin Αvβ3 Imaging.